Epilepsy drug based on research by Icelandic professor now sold in the United States

About 30-years ago, Dr. Sveinbjörn Gizurarson, professor at the Faculty of Pharmacology at the University of Iceland, and his colleagues began work on an emergency treatment for epilepsy designed for delivery as a nasal spray. In December of 2019, this work has culminated in the formal sale of the treatment under the drug-name Nayzilam. Nayzilam is a product of the multinational biopharmaceutical company UCB but licensed from the Icelandic tech company Hananja ehf and the University of Iceland.

The drug is designed for emergency treatment of acute seizures and is expected to greatly increase the quality of life of those suffering from epilepsy. The patents for this specific drug were awarded years in advance of the numerous drug development companies being involved.

To learn more about licensing and research opportunities in Iceland, please visit the Technology Transfer Office (TTO) Iceland, the University of Iceland or Invest in Iceland.

Get in touch

For further information on the benefits of establishing a business in Iceland please feel free to contact us.


Iceland focuses on a favorable business environment, including low corporate tax, availability of land and green energy at competitive prices and efficiency within European legislative framework. Generous support for R&D.

Why Iceland

Along with having one of the lowest corporate tax rate in Europe, Iceland has a highly educated workforce which is ranked among the highest in the world, offers competitively priced renewable energy with an advanced infrastructure making Iceland an ideal location for investors